Systemic treatment and management approaches for medullary thyroid cancer

Vinicius Ernani, Mukesh Kumar, Amy Y. Chen, Taofeek K. Owonikoko

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Although rare, medullary thyroid cancer (MTC) exemplifies the value that ever-expanding knowledge of molecular pathways and mechanisms brings to managing challenging cancers. Although surgery can be curative for MTC in many patients, a substantial proportion of patients present with locoregional or distant metastatic disease. Once distant disease occurs, treatment options are limited, and conventional cancer treatments such as cytotoxic chemotherapy are of minimal benefit. Biomarkers such as calcitonin and carcinoembryonic antigen are important correlates of disease burden as well as predictors of disease progress, including recurrence and survival. MTC is either sporadic (∼75%) or inherited (∼25%) as an autosomal dominant disease. Regardless, germline and somatic mutations, particularly in the rearranged during transfection (RET) proto-oncogene, are key factors in the neoplastic process. Gain-of-function RET mutations result in overactive proteins that lead to abnormal activation of downstream signal transduction pathways, resulting in ligand-independent growth and resistance to apoptotic stimuli. Specific RET mutation variants have been found to correlate with phenotype and natural history of MTC with some defects portending a more aggressive clinical course. Greater understanding of the consequence of the aberrant signaling pathway has fostered the development of targeted therapies. Two small-molecule tyrosine kinase inhibitors, vandetanib and cabozantinib, are currently available as approved agents for the treatment of advanced or progressive MTC and provide significant increases in progression-free survival. Since there have been no head-to-head comparisons, clinicians often select between these agents on the basis of familiarity, patient characteristics, comorbidities, and toxicity profile.

Original languageEnglish (US)
Pages (from-to)89-98
Number of pages10
JournalCancer Treatment Reviews
Volume50
DOIs
StatePublished - Nov 1 2016

Fingerprint

Transfection
Neoplastic Processes
Therapeutics
Mutation
Proto-Oncogenes
Germ-Line Mutation
Carcinoembryonic Antigen
Calcitonin
Natural History
Protein-Tyrosine Kinases
Disease-Free Survival
Comorbidity
Signal Transduction
Neoplasms
Biomarkers
Medullary Thyroid cancer
Ligands
Phenotype
Recurrence
Drug Therapy

Keywords

  • Cabozantinib
  • Medullary thyroid cancer
  • RET mutations
  • Tyrosine kinase inhibitors
  • Vandetanib

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Systemic treatment and management approaches for medullary thyroid cancer. / Ernani, Vinicius; Kumar, Mukesh; Chen, Amy Y.; Owonikoko, Taofeek K.

In: Cancer Treatment Reviews, Vol. 50, 01.11.2016, p. 89-98.

Research output: Contribution to journalReview article

Ernani, Vinicius ; Kumar, Mukesh ; Chen, Amy Y. ; Owonikoko, Taofeek K. / Systemic treatment and management approaches for medullary thyroid cancer. In: Cancer Treatment Reviews. 2016 ; Vol. 50. pp. 89-98.
@article{1891b8226805439685c10a3227fe490d,
title = "Systemic treatment and management approaches for medullary thyroid cancer",
abstract = "Although rare, medullary thyroid cancer (MTC) exemplifies the value that ever-expanding knowledge of molecular pathways and mechanisms brings to managing challenging cancers. Although surgery can be curative for MTC in many patients, a substantial proportion of patients present with locoregional or distant metastatic disease. Once distant disease occurs, treatment options are limited, and conventional cancer treatments such as cytotoxic chemotherapy are of minimal benefit. Biomarkers such as calcitonin and carcinoembryonic antigen are important correlates of disease burden as well as predictors of disease progress, including recurrence and survival. MTC is either sporadic (∼75{\%}) or inherited (∼25{\%}) as an autosomal dominant disease. Regardless, germline and somatic mutations, particularly in the rearranged during transfection (RET) proto-oncogene, are key factors in the neoplastic process. Gain-of-function RET mutations result in overactive proteins that lead to abnormal activation of downstream signal transduction pathways, resulting in ligand-independent growth and resistance to apoptotic stimuli. Specific RET mutation variants have been found to correlate with phenotype and natural history of MTC with some defects portending a more aggressive clinical course. Greater understanding of the consequence of the aberrant signaling pathway has fostered the development of targeted therapies. Two small-molecule tyrosine kinase inhibitors, vandetanib and cabozantinib, are currently available as approved agents for the treatment of advanced or progressive MTC and provide significant increases in progression-free survival. Since there have been no head-to-head comparisons, clinicians often select between these agents on the basis of familiarity, patient characteristics, comorbidities, and toxicity profile.",
keywords = "Cabozantinib, Medullary thyroid cancer, RET mutations, Tyrosine kinase inhibitors, Vandetanib",
author = "Vinicius Ernani and Mukesh Kumar and Chen, {Amy Y.} and Owonikoko, {Taofeek K.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.ctrv.2016.09.006",
language = "English (US)",
volume = "50",
pages = "89--98",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Systemic treatment and management approaches for medullary thyroid cancer

AU - Ernani, Vinicius

AU - Kumar, Mukesh

AU - Chen, Amy Y.

AU - Owonikoko, Taofeek K.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Although rare, medullary thyroid cancer (MTC) exemplifies the value that ever-expanding knowledge of molecular pathways and mechanisms brings to managing challenging cancers. Although surgery can be curative for MTC in many patients, a substantial proportion of patients present with locoregional or distant metastatic disease. Once distant disease occurs, treatment options are limited, and conventional cancer treatments such as cytotoxic chemotherapy are of minimal benefit. Biomarkers such as calcitonin and carcinoembryonic antigen are important correlates of disease burden as well as predictors of disease progress, including recurrence and survival. MTC is either sporadic (∼75%) or inherited (∼25%) as an autosomal dominant disease. Regardless, germline and somatic mutations, particularly in the rearranged during transfection (RET) proto-oncogene, are key factors in the neoplastic process. Gain-of-function RET mutations result in overactive proteins that lead to abnormal activation of downstream signal transduction pathways, resulting in ligand-independent growth and resistance to apoptotic stimuli. Specific RET mutation variants have been found to correlate with phenotype and natural history of MTC with some defects portending a more aggressive clinical course. Greater understanding of the consequence of the aberrant signaling pathway has fostered the development of targeted therapies. Two small-molecule tyrosine kinase inhibitors, vandetanib and cabozantinib, are currently available as approved agents for the treatment of advanced or progressive MTC and provide significant increases in progression-free survival. Since there have been no head-to-head comparisons, clinicians often select between these agents on the basis of familiarity, patient characteristics, comorbidities, and toxicity profile.

AB - Although rare, medullary thyroid cancer (MTC) exemplifies the value that ever-expanding knowledge of molecular pathways and mechanisms brings to managing challenging cancers. Although surgery can be curative for MTC in many patients, a substantial proportion of patients present with locoregional or distant metastatic disease. Once distant disease occurs, treatment options are limited, and conventional cancer treatments such as cytotoxic chemotherapy are of minimal benefit. Biomarkers such as calcitonin and carcinoembryonic antigen are important correlates of disease burden as well as predictors of disease progress, including recurrence and survival. MTC is either sporadic (∼75%) or inherited (∼25%) as an autosomal dominant disease. Regardless, germline and somatic mutations, particularly in the rearranged during transfection (RET) proto-oncogene, are key factors in the neoplastic process. Gain-of-function RET mutations result in overactive proteins that lead to abnormal activation of downstream signal transduction pathways, resulting in ligand-independent growth and resistance to apoptotic stimuli. Specific RET mutation variants have been found to correlate with phenotype and natural history of MTC with some defects portending a more aggressive clinical course. Greater understanding of the consequence of the aberrant signaling pathway has fostered the development of targeted therapies. Two small-molecule tyrosine kinase inhibitors, vandetanib and cabozantinib, are currently available as approved agents for the treatment of advanced or progressive MTC and provide significant increases in progression-free survival. Since there have been no head-to-head comparisons, clinicians often select between these agents on the basis of familiarity, patient characteristics, comorbidities, and toxicity profile.

KW - Cabozantinib

KW - Medullary thyroid cancer

KW - RET mutations

KW - Tyrosine kinase inhibitors

KW - Vandetanib

UR - http://www.scopus.com/inward/record.url?scp=84988357979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988357979&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2016.09.006

DO - 10.1016/j.ctrv.2016.09.006

M3 - Review article

C2 - 27664392

AN - SCOPUS:84988357979

VL - 50

SP - 89

EP - 98

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -